Please use this identifier to cite or link to this item:
|Type:||Artigo de periódico|
|Title:||Prognostic Factors for Hepatocellular Carcinoma Recurrence: Experience With 83 Liver Transplantation Patients|
|Abstract:||Introduction. Orthotopic liver transplantation (OLT) is a rational therapeutic option for early-stage hepatocellular carcinoma (HCC) providing a potential cure and improving survival. Methods. This retrospective study of a longitudinal cohort used an electronic database collected prospectively from September 1997 to May 2010. The variables were gender, age (years), and alpha-fetoprotein (AFP) level (ng/mL). In explanted livers we observed: microvascular or macrovascular invasion, number of nodules and their largest size, Edmondson-Steiner histological differentiation, incidental tumor transarterial chemoembolization (TACE), Milan criteria, and previous down-staging. Results. Five of 83 (6.0%) subjects including 68 (82%) males with a mean time to diagnosis of 9 months experienced tumor relapses. Mean patient age at HCC recurrence was 55.3 years for male and 44.6 years for female subjects. Vascular invasion was detected in 17/83 (20.5%) subjects, namely 2% of macrovascular invasion, and 52.5% with expanded Milan criteria due to an increased number and size of nodules in the explanted livers. An incidental tumor was observed in 29.5% of cases. Preoperative TACE treatment was performed in 13 (15.6%) patients. None of the patients who had a HCC recurrence had undergone TACE. APP level at the time of recurrence was around 1,900 ng/mL. The predictive factor for mortality was nodule size (P = .04; hazard ratio = 0.0269; confidence interval [CI], 95% 0.0094-0.299). Conclusion. Patients with relapses showed the worst survival and tumor size was a predictive factor for recurrence.|
|Editor:||Elsevier Science Inc|
|Citation:||Transplantation Proceedings. Elsevier Science Inc, v. 43, n. 4, n. 1362, n. 1364, 2011.|
|Appears in Collections:||Unicamp - Artigos e Outros Documentos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.